ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) Director Elisha Finney sold 65 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $179.00, for a total transaction of $11,635.00. Following the completion of the sale, the director directly owned 4,871 shares of the company’s stock, valued at approximately $871,909. The trade was a 1.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
ICU Medical Price Performance
ICU Medical stock traded up $1.97 during midday trading on Friday, reaching $179.27. The company had a trading volume of 195,454 shares, compared to its average volume of 283,069. The firm’s fifty day simple moving average is $163.46 and its 200-day simple moving average is $149.76. ICU Medical, Inc. has a 12-month low of $113.37 and a 12-month high of $192.85. The company has a market capitalization of $4.48 billion, a P/E ratio of 75.01, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.37 and a quick ratio of 1.19.
ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.30. The firm had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 8.40% and a net margin of 2.76%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 earnings per share. As a group, equities analysts anticipate that ICU Medical, Inc. will post 7.22 EPS for the current year.
Wall Street Analyst Weigh In
ICUI has been the topic of a number of analyst reports. Zacks Research downgraded ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. KeyCorp increased their price objective on shares of ICU Medical from $187.00 to $189.00 and gave the stock an “overweight” rating in a research report on Friday, November 6th. BTIG Research lifted their target price on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings raised ICU Medical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Piper Sandler upped their target price on shares of ICU Medical from $195.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, November 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $195.20.
View Our Latest Stock Report on ICU Medical
Institutional Investors Weigh In On ICU Medical
Several institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc boosted its holdings in ICU Medical by 26.2% in the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 65 shares in the last quarter. Bessemer Group Inc. increased its stake in ICU Medical by 65.8% in the third quarter. Bessemer Group Inc. now owns 189 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 75 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in ICU Medical by 1.3% during the third quarter. Nisa Investment Advisors LLC now owns 6,088 shares of the medical instruments supplier’s stock worth $977,000 after purchasing an additional 79 shares in the last quarter. California Public Employees Retirement System raised its holdings in ICU Medical by 0.3% during the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after purchasing an additional 90 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its position in shares of ICU Medical by 78.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 239 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 105 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.
ICU Medical Company Profile
ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.
Recommended Stories
- Five stocks we like better than ICU Medical
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
